Archive – Page 290 – Smallcapnetwork

Feature: Biocurex - Is the Best Yet to Come?

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: BioCurex - Is the Best Yet to Come? Long-term readers will know that we have been covering biotech BioCurex (BOCX.PK) for exactly two years. And it's been anything but dull. We've stuck with it because, in our opinion, the company stands to make

Comment (0)

Feature: Universal Detection - Report Reveals Robust Growth Projections.

SmallCap Network /

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Universal Detection - Report Reveals Robust Growth Projections. Dropping Superclick. On the heels of our Trading Alert last week on advanced environmental monitoring company Universal Detection Technology (OTCBB: UDTT), Beacon Equity Research ha

Comment (0)

Feature: Xtreme - Oversold Conditions Ripe.

SmallCap Network /

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Xtreme - Oversold Conditions Ripe. Back in July- specifically from July 6 to July 12, Xtreme doubled. The stock closed at $.12 on July 6, and closed at $.25 a mere six days later. The move from $.12 to $.25 might seem like no big deal, but on a

Comment (0)

Feature: Biophan - Rebound Imminent.

SmallCap Network /

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Biophan - Rebound Imminent. Love or just like it, Biophan (OTCBB: BIPH), has been old reliable in the profit column for subscribers of the SmallCap Digest. In December of '03 when we first featured it at $.35, BIPH was completely unknown and pos

Comment (0)

Feature: Biocurex Steps Up to New Level

SmallCap Network /

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Biocurex Steps Up to New Level BioCurex (BOCX.PK) steps up to new level. BioCurex, one of the Small Cap Digest's stalwart wins, was out with a very significant news announcement pre-open today (release below). For members of the SmallCap Digest,

Comment (0)

Analysis Action

Top Analysis

Timeframe

Recommendation

Risk

Feature: Biocurex - Is the Best Yet to Come?

Feature: Universal Detection - Report Reveals Robust Growth Projections.

Feature: Xtreme - Oversold Conditions Ripe.

Feature: Biophan - Rebound Imminent.

Feature: Biocurex Steps Up to New Level